|1.||Ivy, Percy: 9 articles (04/2012 - 02/2003)|
|2.||Dowlati, Afshin: 4 articles (04/2012 - 12/2005)|
|3.||Prudhomme, Michelle: 4 articles (12/2008 - 02/2003)|
|4.||Fu, Pingfu: 3 articles (04/2012 - 12/2005)|
|5.||Remick, Scot C: 3 articles (02/2011 - 12/2005)|
|6.||Anizon, Fabrice: 3 articles (12/2008 - 08/2003)|
|7.||Kuhn, John G: 3 articles (03/2008 - 07/2003)|
|8.||Krishnamurthi, Smitha: 2 articles (02/2011 - 12/2009)|
|9.||Moreau, Pascale: 2 articles (12/2008 - 08/2003)|
|10.||Pfeiffer, Bruno: 2 articles (12/2008 - 10/2005)|
10/01/1999 - "The study raises the question as to whether topoisomerase I poisoning is important for the antitumour activity of rebeccamycin analogues."
08/15/2003 - "The introduction of an amino group at the 6'-position strongly enhances the capacity of the drugs to interact with DNA but almost abolishes their poisoning effect on topoisomerase I. Unlike the vast majority of rebeccamycin analogues previously studied, the newly designed compounds do not stimulate DNA cleavage by topoisomerase I. The enhanced capacity of the 6'-amino glycosyl rebeccamycin derivatives to bind to DNA likely account for the improved biological profiles. "
12/01/2009 - "Rebeccamycin analogue (RA) is a novel antitumor antibiotic where phase I trials suggested clinical efficacy in patients with biliary cancers. "
12/01/2009 - "Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers."
07/15/2008 - "XL119 is a water-soluble derivative of rebeccamycin with dose-dependent myelosuppression as dose-limiting toxicity in phase 1 studies of solid tumors. "
08/15/2008 - "1,11-Didechloro-6-methyl-4'-O-demethyl rebeccamycin (JDC-108), a rebeccamycin analog possessing potent anti-tumor activities, was prepared via a concise one-pot strategy in good yield. "
03/01/2008 - "With a global response rate of 3% observed in children with relapsed CNS and non-CNS solid tumors, further development of Rebeccamycin analogue in pediatric solid tumors is not recommended."
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/01/2005 - "Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer."
10/01/2005 - "The cytotoxicities of the newly synthesized compounds toward four tumor cell lines, one murine leukemia (L1210) and three human tumor cell lines (prostate carcinoma DU145, colon carcinoma HT29, and non-small cell lung carcinoma A549) have been evaluated and compared to those of rebeccamycin and parent non-aza and aza compounds."
|4.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
|5.||Hematologic Neoplasms (Hematological Malignancy)
|1.||Type I DNA Topoisomerases (Topoisomerase I)
|2.||DNA (Deoxyribonucleic Acid)
|3.||becatecarin (XL 119)
|6.||Protein Kinase Inhibitors
|9.||Protein Kinase C
|1.||Drug Therapy (Chemotherapy)